UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV

International journal of clinical oncology, 2019-07, Vol.24 (7), p.731-770

2019

Volltextzugriff (PDF)

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer

Scientific reports, 2018-10, Vol.8 (1), p.14896-9, Article 14896

2018

Volltextzugriff (PDF)

Evaluation of a Tool that Enables Cancer Patients to Participate in the Decision-Making Process during Treatment Selection

Journal of Nippon Medical School = Nippon Ika Daigaku zasshi, 2021-08, Vol.88 (4), p.273-282, Article JNMS.2021_88-401

2021

Volltextzugriff (PDF)

Clinicopathological Characteristics of Everolimus-Associated Interstitial Lung Disease: A Single-Center Consecutive Analysis

Journal of Nippon Medical School = Nippon Ika Daigaku zasshi, 2024-04, Vol.91 (2), p.207-217, Article JNMS.2024_91-211

2024

Volltextzugriff (PDF)

A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027

BMC cancer, 2021-03, Vol.21 (1), p.208-10, Article 208

2021

Volltextzugriff (PDF)

Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer

Internal Medicine, 2021/02/15, Vol.60(4), pp.591-594

2021

Volltextzugriff (PDF)

Real-world outcomes of chemotherapy for lung cancer patients undergoing hemodialysis: A multicenter retrospective cohort study (NEJ-042)

Lung cancer (Amsterdam, Netherlands), 2022-10, Vol.172, p.1-8

2022

Volltextzugriff (PDF)

Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer

Thoracic cancer, 2020-04, Vol.11 (4), p.1052-1060

2020

Volltextzugriff (PDF)

miR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma

Oncology reports, 2014-12, Vol.32 (6), p.2365-2372

2014

Volltextzugriff (PDF)

PD-L1 Expression Status Predicting Survival in Pulmonary Pleomorphic Carcinoma

Anticancer research, 2021-05, Vol.41 (5), p.2501-2509

2021

Volltextzugriff (PDF)

Exacerbation of Idiopathic Interstitial Pneumonias Associated with Lung Cancer Therapy

Internal Medicine, 2009, Vol.48(9), pp.665-672

2009

Volltextzugriff (PDF)

Interstitial lung disease associated with nanoparticle albumin-bound paclitaxel treatment in patients with lung cancer

Japanese journal of clinical oncology, 2019-02, Vol.49 (2), p.165-173

2019

Volltextzugriff (PDF)

Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation

Oncogene, 2002-09, Vol.21 (39), p.6082-6090

2002

Volltextzugriff (PDF)

Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia

Respiratory investigation, 2019-11, Vol.57 (6), p.512-533

2019

Volltextzugriff (PDF)

Chemotherapy for Lung Cancer Patients with Comorbidities

Haigan. Lung cancer, 2022-12, Vol.62 (Supplement), p.967-969

Minegishi, Yuji

2022

Volltextzugriff (PDF)

Breast Cancer Resistance Protein Impacts Clinical Outcome in Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer

Clinical cancer research, 2004-03, Vol.10 (5), p.1691-1697

2004

Volltextzugriff (PDF)

Severe Pneumonitis with Alveolar Hemorrhage Associated with Herbal Medicines: A Case Report

Journal of Nippon Medical School = Nippon Ika Daigaku zasshi, 2019-10, Vol.86 (5), p.296-300

2019

Volltextzugriff (PDF)

Organizing Pneumonia after Nivolumab Treatment in a Patient with Pathologically Proven Idiopathic Pulmonary Fibrosis

Journal of Nippon Medical School = Nippon Ika Daigaku zasshi, 2019-01, Vol.86 (1), p.43-47

2019

Volltextzugriff (PDF)

Standard versus low‐dose nab‐paclitaxel in previously treated patients with advanced non‐small cell lung cancer: A randomized phase II trial (JMTO LC14‐01)

Cancer medicine (Malden, MA), 2023-04, Vol.12 (8), p.9133-9143

2023

Volltextzugriff (PDF)

Feasibility Study of Combined Chemotherapy for Advanced Lung Cancer with Idiopathic Interstitial Pneumonias and Proteomic Analysis to Detect Risk Factors for Their Acute Exacerbation

Journal of Nippon Medical School = Nippon Ika Daigaku zasshi, 2011, Vol.78 (1), p.50-51

Minegishi, Yuji

2011

Volltextzugriff (PDF)

The Author Reply: Acute Exacerbation of IIPs Related to Anticancer Treatment for Lung Cancer

Internal Medicine, 2009, Vol.48(18), pp.1723-1723

Minegishi, Yuji

2009

Volltextzugriff (PDF)

Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060

JTO clinical and research reports, 2024-04, Vol.5 (4), p.100655-100655, Article 100655

2024

Volltextzugriff (PDF)

Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis

Oxford Medical Case Reports, 2018-11, Vol.2018 (11), p.omy094

2018

Volltextzugriff (PDF)

Histone deacetylase inhibitor enhances sensitivity of non‐small‐cell lung cancer cells to 5‐FU/S‐1 via down‐regulation of thymidylate synthase expression and up‐regulation of p21waf1/cip1 expression

Cancer science, 2010-06, Vol.101 (6), p.1424-1430

2010

Volltextzugriff (PDF)

1 – 25 von 175

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(133)
Mit Volltextzugriff
(148)

Publikationsform

Sprache

Englisch
(162)
Japanisch
(55)

Erscheinungsjahr

n.n

Thema

Science & Technology
(95)
Life Sciences & Biomedicine
(86)
Humans
(56)
Oncology
(52)
Lung Neoplasms - Drug Therapy
(37)
Male
(35)
Female
(34)
Lung Cancer
(34)
Aged
(31)
Chemotherapy
(24)
Middle Aged
(24)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(23)
Tumors
(19)
Biological And Medical Sciences
(17)
Lung Neoplasms - Pathology
(17)
Respiratory System
(16)
Lung Neoplasms - Genetics
(15)
Adult
(14)
Aged, 80 And Over
(12)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(12)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer

Evaluation of a Tool that Enables Cancer Patients to Participate in the Decision-Making Process during Treatment Selection

Clinicopathological Characteristics of Everolimus-Associated Interstitial Lung Disease: A Single-Center Consecutive Analysis

A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027

Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer

Real-world outcomes of chemotherapy for lung cancer patients undergoing hemodialysis: A multicenter retrospective cohort study (NEJ-042)

Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer

miR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma

PD-L1 Expression Status Predicting Survival in Pulmonary Pleomorphic Carcinoma

Exacerbation of Idiopathic Interstitial Pneumonias Associated with Lung Cancer Therapy

Interstitial lung disease associated with nanoparticle albumin-bound paclitaxel treatment in patients with lung cancer

Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation

Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia

Chemotherapy for Lung Cancer Patients with Comorbidities

Breast Cancer Resistance Protein Impacts Clinical Outcome in Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer

Severe Pneumonitis with Alveolar Hemorrhage Associated with Herbal Medicines: A Case Report

Organizing Pneumonia after Nivolumab Treatment in a Patient with Pathologically Proven Idiopathic Pulmonary Fibrosis

Standard versus low‐dose nab‐paclitaxel in previously treated patients with advanced non‐small cell lung cancer: A randomized phase II trial (JMTO LC14‐01)

Feasibility Study of Combined Chemotherapy for Advanced Lung Cancer with Idiopathic Interstitial Pneumonias and Proteomic Analysis to Detect Risk Factors for Their Acute Exacerbation

Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan

The Author Reply: Acute Exacerbation of IIPs Related to Anticancer Treatment for Lung Cancer

Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060

Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis

Histone deacetylase inhibitor enhances sensitivity of non‐small‐cell lung cancer cells to 5‐FU/S‐1 via down‐regulation of thymidylate synthase expression and up‐regulation of p21waf1/cip1 expression

Suchergebnisse filtern